Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

9

Revenue 2017

Lantus

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Lantus was produced by Sanofi.

20 for 2020 – Five pharma leaders to watch in 2020

20 for 2020 – Five pharma leaders to watch in 2020

protection for Lantus (insulin glargine) – as well as cardiovascular disease research.

Sanofi narrows focus, shedding diabetes and cardiovascular research

Sanofi narrows focus, shedding diabetes and cardiovascular research year. Its insulin Lantus was the top selling product across its diabetes business, bringing in 751m, a drop of almost 17.5% from the same period last year.

Sanofi’s new CEO cuts first deal, adding Synthorx for $2.5bn

Sanofi’s new CEO cuts first deal, adding Synthorx for $2.5bn Sanofi has had a challenging few years following the loss of patent protection for its former diabetes cash cow Lantus (insulin glargine), with some pipeline successes – notably atopic dermatitis and asthma

Sanofi said to be looking at options for $30bn consumer health unit

Sanofi said to be looking at options for $30bn consumer health unit Sanofi has had a difficult few years following the loss of patent protection for its former diabetes cash cow Lantus (insulin glargine), with some pipeline successes – notably atopic dermatitis and asthma

Sanofi reveals positive phase 3 results for long-acting insulin Toujeo

Sanofi reveals positive phase 3 results for long-acting insulin Toujeo has compared it to Lantus (insulin glargine 100 units/mL), which lost its patent last year. ... The drug, Zynquista (sotagliflozin), was a key element in Sanofi’s plans to rebuild its diabetes franchise following the loss of patent protection for its

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa
Ben Speller shares his thoughts on the value of disease specific congresses...
OPEN Health use PR to support clinical trial recruitment
International Clinical Trials Day finds clinical research in the spotlight like never before, with any news coming from the many studies into potential vaccines and treatments for SARS-CoV-2...
Covid-19: what could it mean for the diabetic population?
Steve How and Oli Hudson, of Wilmington Healthcare, assess the scale of the diabetes crisis and how coronavirus might impact on it...

Infographics